Royalty Pharma (RPRX) Debt Ratio (2019 - 2026)

Royalty Pharma has disclosed Debt Ratio across 8 years of filings, most recently posting 0.45 for Q1 2026.

• Debt Ratio for Q1 2026 came in at 0.45, up 4.48% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.45 (up 4.48% YoY), and the FY2025 annual result was 0.46, up 9.2% from the prior year.
• Debt Ratio came in at 0.45 for Q1 2026 at Royalty Pharma, down from 0.46 in the prior quarter.
• In the past five years, Debt Ratio ranged from a high of 0.46 in Q3 2025 to a low of 0.35 in Q3 2022.
• The 5-year median for Debt Ratio is 0.42 (2024), against an average of 0.41.
• Across the five-year window, Debt Ratio decreased 13.43% in 2022 and advanced 13.67% in 2025, its largest moves.
• Royalty Pharma's Debt Ratio stood at 0.42 in 2022, then retreated by 11.51% to 0.37 in 2023, then advanced by 11.54% to 0.42 in 2024, then advanced by 9.2% to 0.46 in 2025, then slipped by 0.92% to 0.45 in 2026.
• The last three Debt Ratio figures came in at 0.45 (Q1 2026), 0.46 (Q4 2025), and 0.46 (Q3 2025), per Business Quant data.